These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
3. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice. Striano P; McMurray R; Santamarina E; Falip M Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492 [TBL] [Abstract][Full Text] [Related]
4. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353 [TBL] [Abstract][Full Text] [Related]
5. Rufinamide in children and adults in routine clinical practice. Jaraba S; Santamarina E; Miró J; Toledo M; Molins A; Burcet J; Becerra JL; Raspall M; Pico G; Miravet E; Cano A; Fossas P; Fernández S; Falip M Acta Neurol Scand; 2017 Jan; 135(1):122-128. PubMed ID: 26923380 [TBL] [Abstract][Full Text] [Related]
6. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data. Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis. Sharawat IK; Panda PK; Panda P; Dawman L Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Rufinamide in the Treatment of Idiopathic Generalized Epilepsy With Atypical Evolution: Case Report and Review of the Literature. Albini M; Morano A; Fanella M; Lapenta L; Casciato S; Fattouch J; Manfredi M; Giallonardo AT; Di Bonaventura C Clin EEG Neurosci; 2016 Apr; 47(2):162-6. PubMed ID: 25420625 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022. Arzimanoglou A; Pringsheim M; Kluger GJ; Genton P; Perdomo C; Malhotra M Epilepsy Behav; 2021 Sep; 124():108275. PubMed ID: 34509883 [TBL] [Abstract][Full Text] [Related]
11. Aggravation of atonic seizures by rufinamide: A case report. Bektaş G; Çalışkan M; Aydın A; Pembegül Yıldız E; Tatlı B; Aydınlı N; Özmen M Brain Dev; 2016 Aug; 38(7):654-7. PubMed ID: 26906013 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229 [TBL] [Abstract][Full Text] [Related]
13. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. Motte J; Trevathan E; Arvidsson JF; Barrera MN; Mullens EL; Manasco P N Engl J Med; 1997 Dec; 337(25):1807-12. PubMed ID: 9400037 [TBL] [Abstract][Full Text] [Related]
14. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K; Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273 [TBL] [Abstract][Full Text] [Related]
15. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome. Kim SH; Kang HC; Lee JS; Kim HD Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208 [TBL] [Abstract][Full Text] [Related]
16. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Capovilla G; Verrotti A; Mangano S; Balestri A; Curatolo P; Pascotto A Seizure; 2010 Nov; 19(9):587-91. PubMed ID: 20888268 [TBL] [Abstract][Full Text] [Related]
17. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients. Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364 [TBL] [Abstract][Full Text] [Related]
18. Rufinamide for the treatment of Lennox-Gastaut syndrome. Besag FM Expert Opin Pharmacother; 2011 Apr; 12(5):801-6. PubMed ID: 21348771 [TBL] [Abstract][Full Text] [Related]
19. Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome. Ferrie CD Expert Rev Neurother; 2010 Jun; 10(6):851-60. PubMed ID: 20518600 [TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Benedict A; Verdian L; Maclaine G Pharmacoeconomics; 2010; 28(3):185-99. PubMed ID: 20151724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]